The binding of human complement component C4 to antibody-antigen aggregates - PubMed (original) (raw)
The binding of human complement component C4 to antibody-antigen aggregates
R D Campbell et al. Biochem J. 1980.
Abstract
The binding of human complement component C4 to antibody-antigen aggregates and the nature of the interaction have been investigated. When antibody-antigen aggregates with optimal C1 bound are incubated with C4, the C4 is rapidly cleaved to C4b, but only a small fraction (1-2%) is bound to the aggregates, the rest remaining in the fluid phase as inactive C4b. It has been found that C4b and th antibody form a very stable complex, due probably to the formation of a covalent bond. On reduction of the C4b-immunoglobulin G (IgG) complex, the beta and gamma chains, but not the alpha' chain, of C4b are released together with all the light chain, but only about half of the heavy chain of IgG. The reduced aggregates contain two main higher-molecular-weight complexes, one shown by the use of radioactive components to contain both IgG and C4b and probably therefore the alpha' chain of C4b and the heavy chain of IgG, and the other only C4b and probably an alpha' chain dimer. The aggregates with bound C1 and C4b show maximal C3 convertase activity, in the presence of excess C2, when the alpha'-H chain component is in relatively highest amounts. When C4 is incubated with C1s in the absence of aggregates, up to 15% of a C4b dimer is formed, which on reduction gives an alpha' chain complex, probably a dimer. The apparent covalent interaction between C4b and IgG and between C4b and other C4b molecules cannot be inhibited by iodoacetamide and hence cannot be catalysed by transglutaminase (factor XIII). The reaction is, however, inhibited by cadaverine and putrescine and 14C-labelled putrescine is incorporated into C4, again by a strong, probably covalent, bond. It is suggested that a reactive group, possibly an acyl group, is generated when C4 is activated by C1 and that this reactive group can react with IgG, with another C4 molecule, or with water.
Similar articles
- The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
Gadd KJ, Reid KB. Gadd KJ, et al. Biochem J. 1981 May 1;195(2):471-80. doi: 10.1042/bj1950471. Biochem J. 1981. PMID: 7316962 Free PMC article. - Formation of covalent complexes between the fourth component of human complement and IgG immune aggregates.
Alcolea JM, Antón LC, Marqués G, Sánchez-Corral P, Vivanco F. Alcolea JM, et al. Complement. 1987;4(1):21-32. doi: 10.1159/000463004. Complement. 1987. PMID: 3568629 - Binding of human C4 to C-reactive protein-pneumococcal C-polysaccharide complexes during activation of the classical complement pathway.
Volanakis JE, Narkates AJ. Volanakis JE, et al. Mol Immunol. 1983 Nov;20(11):1201-7. doi: 10.1016/0161-5890(83)90143-8. Mol Immunol. 1983. PMID: 6558418 - The Croonian Lecture, 1980. The complex proteases of the complement system.
Porter RR. Porter RR. Proc R Soc Lond B Biol Sci. 1980 Nov 28;210(1181):477-98. doi: 10.1098/rspb.1980.0148. Proc R Soc Lond B Biol Sci. 1980. PMID: 6110208 Review. - The internal thioester and the covalent binding properties of the complement proteins C3 and C4.
Law SK, Dodds AW. Law SK, et al. Protein Sci. 1997 Feb;6(2):263-74. doi: 10.1002/pro.5560060201. Protein Sci. 1997. PMID: 9041627 Free PMC article. Review.
Cited by
- Complement is activated by elevated IgG3 hexameric platforms and deposits C4b onto distinct antibody domains.
Abendstein L, Dijkstra DJ, Tjokrodirijo RTN, van Veelen PA, Trouw LA, Hensbergen PJ, Sharp TH. Abendstein L, et al. Nat Commun. 2023 Jul 7;14(1):4027. doi: 10.1038/s41467-023-39788-5. Nat Commun. 2023. PMID: 37419978 Free PMC article. - A fully recombinant human IgG1 Fc multimer (GL-2045) inhibits complement-mediated cytotoxicity and induces iC3b.
Zhou H, Olsen H, So E, Mérigeon E, Rybin D, Owens J, LaRosa G, Block DS, Strome SE, Zhang X. Zhou H, et al. Blood Adv. 2017 Mar 14;1(8):504-515. doi: 10.1182/bloodadvances.2016001917. eCollection 2017 Mar 14. Blood Adv. 2017. PMID: 29296968 Free PMC article. - Activated complement components and complement activator molecules on the surface of cell-derived microparticles in patients with rheumatoid arthritis and healthy individuals.
Biró E, Nieuwland R, Tak PP, Pronk LM, Schaap MC, Sturk A, Hack CE. Biró E, et al. Ann Rheum Dis. 2007 Aug;66(8):1085-92. doi: 10.1136/ard.2006.061309. Epub 2007 Jan 29. Ann Rheum Dis. 2007. PMID: 17261534 Free PMC article. - The binding of complement component C3 to antibody-antigen aggregates after activation of the alternative pathway in human serum.
Gadd KJ, Reid KB. Gadd KJ, et al. Biochem J. 1981 May 1;195(2):471-80. doi: 10.1042/bj1950471. Biochem J. 1981. PMID: 7316962 Free PMC article. - Autolytic fragmentation of complement components C3 and C4 under denaturing conditions, a property shared with alpha 2-macroglobulin.
Sim RB, Sim E. Sim RB, et al. Biochem J. 1981 Jan 1;193(1):129-41. doi: 10.1042/bj1930129. Biochem J. 1981. PMID: 7305917 Free PMC article.
References
- J Exp Med. 1967 Feb 1;125(2):359-80 - PubMed
- Immunochemistry. 1966 Mar;3(2):111-35 - PubMed
- Proc Natl Acad Sci U S A. 1977 Jul;74(7):2701-5 - PubMed
- FEBS Lett. 1979 Jul 1;103(1):156-61 - PubMed
- Nature. 1970 Aug 15;227(5259):680-5 - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous